These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 7865237)

  • 1. Biochemical parameters as prognostic factors in prostatic adenocarcinoma.
    Vesalainen S; Lipponen P; Talja M; Syrjänen K
    Acta Oncol; 1995; 34(1):53-9. PubMed ID: 7865237
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progression and survival in prostatic adenocarcinoma: a comparison of clinical stage, Gleason grade, S-phase fraction and DNA ploidy.
    Vesalainen S; Nordling S; Lipponen P; Talja M; Syrjänen K
    Br J Cancer; 1994 Aug; 70(2):309-14. PubMed ID: 8054280
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A prognostic score for prostatic adenocarcinoma based on clinical, histological, biochemical and cytometric data from the primary tumour.
    Lipponen P; Vesalainen S; Kasurinen J; Ala-Opas M; Syrjänen K
    Anticancer Res; 1996; 16(4A):2095-100. PubMed ID: 8712749
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nuclear morphometry is of independent prognostic value only in T1 prostatic adenocarcinomas.
    Vesalainen S; Lipponen P; Talja M; Kasurinen J; Syrjänen K
    Prostate; 1995 Aug; 27(2):110-7. PubMed ID: 7638083
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proliferating cell nuclear antigen and p53 expression as prognostic factors in T1-2M0 prostatic adenocarcinoma.
    Vesalainen SL; Lipponen PK; Talja MT; Alhava EM; Syrjänen KJ
    Int J Cancer; 1994 Jul; 58(2):303-8. PubMed ID: 7913085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Implications of serum bone turnover markers in prostate cancer patients with bone metastasis.
    Kamiya N; Suzuki H; Yano M; Endo T; Takano M; Komaru A; Kawamura K; Sekita N; Imamoto T; Ichikawa T
    Urology; 2010 Jun; 75(6):1446-51. PubMed ID: 20206975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic Factors for Survival in Noncastrate Metastatic Prostate Cancer: Validation of the Glass Model and Development of a Novel Simplified Prognostic Model.
    Gravis G; Boher JM; Fizazi K; Joly F; Priou F; Marino P; Latorzeff I; Delva R; Krakowski I; Laguerre B; Walz J; Rolland F; Théodore C; Deplanque G; Ferrero JM; Pouessel D; Mourey L; Beuzeboc P; Zanetta S; Habibian M; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Labourey JL; Machiels JP; El Kouri C; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Soulie M; Oudard S
    Eur Urol; 2015 Aug; 68(2):196-204. PubMed ID: 25277272
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mitotic activity and prognosis in prostatic adenocarcinoma.
    Vesalainen S; Lipponen P; Talja M; Syrjänen K
    Prostate; 1995 Feb; 26(2):80-6. PubMed ID: 7855001
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate-specific antigen cancer volume: a significant prognostic factor in prostate cancer patients at intermediate risk of failing radiotherapy.
    Lankford SP; Pollack A; Zagars GK
    Int J Radiat Oncol Biol Phys; 1997 May; 38(2):327-33. PubMed ID: 9226319
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of alkaline phosphatase flare in patients with metastatic prostate cancer treated with endocrine therapy.
    Nakashima J; Ozu C; Nishiyama T; Oya M; Ohigashi T; Asakura H; Tachibana M; Murai M
    Urology; 2000 Nov; 56(5):843-7. PubMed ID: 11068314
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Prognostic value of DNA ploidy and nuclear morphometry in metastatic prostate cancer].
    Martínez Jabaloyas JM; Jiménez Sánchez A; Ruiz Cerdá JL; Sanz Chinesta S; Sempere A; Jiménez Cruz JF
    Actas Urol Esp; 2004 Apr; 28(4):298-307. PubMed ID: 15248401
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor vascularity and basement membrane structure as prognostic factors in T1-2MO prostatic adenocarcinoma.
    Vesalainen S; Lipponen P; Talja M; Alhava E; Syrjänen K
    Anticancer Res; 1994; 14(2B):709-14. PubMed ID: 8010731
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Results of the primary treatment in T1-3M0 prostatic adenocarcinoma are dependent on tumour biology.
    Vesalainen S; Lipponen P; Nordling S; Talja M; Syrjänen K
    Anticancer Res; 1995; 15(2):569-73. PubMed ID: 7763039
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunohistochemical prostatic acid phosphatase level as a prognostic factor of prostatic carcinoma.
    Sakai H; Shiraishi K; Minami Y; Yushita Y; Kanetake H; Saito Y
    Prostate; 1991; 19(3):265-72. PubMed ID: 1946042
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum acid phosphatase level and biochemical recurrence following radical prostatectomy for men with clinically localized prostate cancer.
    Han M; Piantadosi S; Zahurak ML; Sokoll LJ; Chan DW; Epstein JI; Walsh PC; Partin AW
    Urology; 2001 Apr; 57(4):707-11. PubMed ID: 11306387
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma.
    Cheng L; Jones TD; Lin H; Eble JN; Zeng G; Carr MD; Koch MO
    J Urol; 2005 Dec; 174(6):2181-5. PubMed ID: 16280760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The flare in serum alkaline phosphatase activity after orchiectomy: a valuable negative prognostic index for progression-free survival in prostatic carcinoma.
    Pelger RC; Lycklama A Nijeholt GA; Zwinderman AH; Papapoulos SE; Hamdy NA
    J Urol; 1996 Jul; 156(1):122-6. PubMed ID: 8648772
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic significance of serum alkaline phosphatase and lactate dehydrogenase levels in patients with unresectable advanced gastric cancer.
    Namikawa T; Ishida N; Tsuda S; Fujisawa K; Munekage E; Iwabu J; Munekage M; Uemura S; Tsujii S; Tamura T; Yatabe T; Maeda H; Kitagawa H; Kobayashi M; Hanazaki K
    Gastric Cancer; 2019 Jul; 22(4):684-691. PubMed ID: 30417313
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Multivariate analysis of prognostic factors in patients with prostatic cancer].
    Miyamoto T; Yuasa M; Furukawa A; Tamura M; Kawanishi Y; Numata A; Imagawa A; Kagawa S
    Hinyokika Kiyo; 1991 Dec; 37(12):1663-8. PubMed ID: 1785390
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High stromal hyaluronan level is associated with poor differentiation and metastasis in prostate cancer.
    Lipponen P; Aaltomaa S; Tammi R; Tammi M; Agren U; Kosma VM
    Eur J Cancer; 2001 May; 37(7):849-56. PubMed ID: 11313172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.